Sienna Biopharmaceuticals Enters $40 Million Term Loan

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
36
Sienna Biopharmaceuticals Enters $40 Million Term Loan Agreement

WESTLAKE VILLAGE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced that the Company has entered a $40 million term loan agreement with Silicon Valley Bank. Sienna drew $30 million on closing. The remaining tranche of $10 million may be drawn at the Company’s discretion, subject to certain terms and conditions. Sienna will make interest-only payments for the first 24 months of the 60-month loan term.

“We are pleased to announce that we have added $30 million to our cash balance on very favorable terms,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “We believe this additional, non-dilutive capital strengthens our balance sheet, extending our cash runway beyond our nine clinical data inflection points coming over the next three quarters and getting us at least into the third quarter of 2019. It also gives us greater financial flexibility as we continue to advance our innovative multi-asset pipeline that seeks to address significant unmet medical needs and create shareholder value.”

Pipeline Overview

Sienna’s pipeline currently includes five clinical-stage programs and nine ongoing clinical trials: (from the Company’s Topical by Design™ platform)

  • SNA-120 for the treatment of pruritus associated with psoriasis and the underlying psoriasis; Phase 2b top-line results expected in the first quarter of 2019
  • SNA-125 for the treatment of atopic dermatitis; Phase 1/2 proof-of-concept results expected in the fourth quarter of 2018
  • SNA-125 for the treatment of psoriasis; Phase 1/2 proof-of-concept results expected in the third quarter of 2018

(from the Company’s Topical Photoparticle Therapy™ platform)

  • SNA-001 for the treatment of acne
    • pivotal results with the 1064 nm and with the 810 nm wavelength lasers expected in the third quarter of 2018
    • pivotal results with the 755 nm wavelength laser expected in the fourth quarter of 2018
  • SNA-001 for the reduction of light-pigmented hair
    • pivotal results with the 1064 nm wavelength laser expected in the fourth quarter of 2018
    • pivotal results with the 810 nm and with the 755 nm wavelength lasers expected in the first quarter of 2019

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.

For more information, visit the Company’s website at www.SiennaBio.com .

Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to the statements by Sienna’s Chief Executive Officer and other statements regarding Sienna’s ability to satisfy certain terms and conditions or to draw additional capital from the remaining tranche of the term loan, the sufficiency of the Company’s cash resources and related operating cash runway and the timing of data readouts from Sienna’s clinical programs. Such forward-looking statements involve substantial risks and uncertainties that could cause Sienna’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the pharmaceutical drug and medical device development processes, including regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing pharmaceutical drug and medical device products, Sienna’s ability to successfully protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations and the availability or commercial potential of Sienna’s drug candidates. Sienna undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Sienna’s most recent Annual Report on Form 10-K and any subsequent current and periodic reports filed with the Securities and Exchange Commission.

Contact:

Sean Andrews (Investors) sandrews@siennabio.com 818-629-2244

Crystal Muilenburg (Media) cmuilenburg@siennabio.com 818-584-1035

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 16

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Neurotrope, Inc. Achieves New Milestone with Stock Surge

Updated Category News Views 147

Neurotrope, Inc. Reaches New Stock Milestone Neurotrope, Inc. (NASDAQ: NTRP) has recently achieved a significant milestone in the stock market, soaring to a 52-week high with its price reaching $7.00. This impressive climb indicates a remarkable 124.95% increase over the past year, showcasing strong investor interest and confidence in the company's future prospects. The...

Continue Reading
Lil Nas X's Legal Challenges and Public Struggles Unfold

Updated Category News Views 284

Lil Nas X Pleads Not Guilty to Serious Charges Grammy-winning musician Lil Nas X has recently made headlines for pleading not guilty to multiple felony charges stemming from an incident involving police officers. This situation arose when he was found walking unclothed on the streets of Los Angeles. Understanding the Legal Battle Ahead The rapper, known legally as Montero...

Continue Reading
Exyte's Strategic Acquisition of TTP Group Enhanced Operations

Updated Category News Views 51

Exyte Acquires TTP Group to Strengthen Engineering Expertise Exyte, a leader in high-tech facility engineering, has officially completed the acquisition of TTP Group, enhancing its operations and expertise especially in the biopharma and life sciences sectors. This acquisition marks a significant milestone for Exyte as it melds TTP's capabilities with its own, aiming to...

Continue Reading
Unveiling Health Innovations: Zepp Health at CES 2024 Events

Updated Category News Views 372

Zepp Health Showcases Innovative Technologies at CES Zepp Health Corporation (NYSE: ZEPP), a leader in health technology and smart wearables, is excited to announce its participation in significant media events like Pepcom and ShowStoppers at CES. These occasions will showcase Zepp Health's latest advancements in smart wearables and health technologies, aimed at...

Continue Reading
Meridian Locks $186M Loan for NJ Condo Project

Updated Category News Views 163

New Jersey's Coastline Gets a $186 Million Facelift Here's a move that'll shake the Jersey Shore awake: Meridian Capital Group's just put their money where the sand is with a massive $186 million scoop for a new high-end condominium project in Asbury Park. You couldn't make up a better setting—a beachfront spot ripe for some high-end living. But let's not get too...

Continue Reading